PillRx only · Kit · Subcutaneous
Leuprolide Acetate
Brands: Eligard
6 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US9 NDCs
6 active makers
6 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$199.631
Latest avg · May 20, 2026
-23%
Since Dec 17, 2025
6
Active US suppliers
56%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
1.1K
Rx · 2026 Q1
1.2K
Units dispensed
-46%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it6 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| TOLMAR Inc. | unknown | 4 | SUPPLYING |
| NorthStar RxLLC | unknown | 1 | SUPPLYING |
| UBI Pharma Inc. | unknown | 1 | SUPPLYING |
| PAI Holdings, LLC dba PAI Pharma | unknown | 1 | SUPPLYING |
| Amneal Pharmaceuticals LLC | unknown | 1 | SUPPLYING |
| Meitheal Pharmaceuticals Inc. | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Sep 12, 2023RECALLRecall (Class III): Eligard (leuprolide acetate) for injectable suspension, 7.5 mg every month, Sterile, Rx Only, Must be reconstituted bef…
Superpotent Drug - Higher than expected levels of leuprolide acetate in the constituted product. — Recalling firm: Tolmar, Inc. — Nationwide in the US.